Results 181 to 190 of about 8,133 (247)

Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Aims This study examined changes in body composition and bone mineral density (BMD) over 12 months in people with obesity and type 1 diabetes (T1D) treated with a GLP‐1 receptor agonist alone (GLP‐1RA) or a dual glucose‐dependent insulinotropic polypeptide (GIP/GLP‐1RA).
Ebaa Al Ozairi, Mohammad Irshad, Jumana Alkandri, Anant Mashankar, Stuart R. Gray, Carel W. le Roux   +5 more
wiley   +1 more source

Sleep and circadian effects on the incretin system. [PDF]

Curr Sleep Med Rep
Yuan RK, Zitting KM.
europepmc   +1 more source

Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
This prospective observational study evaluated changes in dietary patterns and body composition after 3 months of oral semaglutide treatment in people with Type 2 diabetes. Oral semaglutide was associated with reduced energy intake, salt intake and body fat while preserving handgrip strength.
Mika Sawada, Naoko Nakanishi, Masakazu Aihara, Kanako Ohkuma, Shoko Hamano, Yoshitaka Sakurai, Rie Sekine, Satoshi Usami, Toshimasa Yamauchi, Naoto Kubota   +9 more
wiley   +1 more source

Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting. [PDF]

Biomolecules
de la Monte SM, Tong M, Carlson RI, Sutherland G.   +3 more
europepmc   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Zakariye Isak Mohamed, Abdinasir Adam Shidane, Abdullahi Mohamud Abdiasis, Mohamed Hassan Hussein, Ayaanle Osman Ibrahim, Anas Ali Abdi, Kowthar Ismail Hashi, Mohamed Abdullahi Mohamud, Ali Jimale Mohamed   +8 more
wiley   +1 more source

Recent Updates on Diabetes and Bone. [PDF]

Int J Mol Sci
Brunetti G.
europepmc   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes. [PDF]

Sci Rep
Takemoto M, Zhang BS, Hayashi A, Yamagata H, Yoshida Y, Koshizaka M, Onishi S, Yamaga M, Yoshida T, Hashimoto T, Ohtake N, Ishikawa T, Takizawa H, Hiwasa T.   +13 more
europepmc   +1 more source

Qualitative and Quantitative Health‐Related Quality‐of‐Life Outcomes From an 8‐year Follow‐Up After Gastric Bypass Surgery in People With Type 2 Diabetes

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Quality of life after gastric bypass is a multidimensional, evolving process influenced by changing health, life circumstances and psychosocial factors over time, including: physical functioning, psychological well‐being, body adaptation, social supports and life events.
Giovanni Fanni, Petros Katsogiannos, Magnus Sundbom, Janeth Leksell, Eva Randell   +4 more
wiley   +1 more source

Incretins: mechanistic insights, clinical realities, and translational perspectives in type 2 diabetes and obesity. [PDF]

Diabetol Int
Yabe D.
europepmc   +1 more source